Recombinant Human CD158K/KIR3DL2 protein (rFc Tag)
Species
Human
Purity
>90 %, SDS-PAGE
Tag
rFc Tag
Activity
not tested
Cat no : Eg3778
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <0.1 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Human KIR3DL2 protein Leu22-His340 (Accession# P43630-1) with a rabbit IgG Fc tag at the C-terminus. |
| GeneID | 3812 |
| Accession | P43630-1 |
| PredictedSize | 61.3 kDa |
| SDS-PAGE | 75-85 kDa, reducing (R) conditions |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
KIR3DL2, also known as CD158k, is an inhibitory receptor expressed by natural killer (NK) cells and a subset of CD8+ T cells. It plays a role in immune regulation by binding to HLA class I molecules, specifically HLA-A3 and HLA-A11, in a peptide-dependent fashion. KIR3DL2 can also function as an innate immune receptor for delivering CpG DNA to TLR9 in NK cells, highlighting its role in both adaptive and innate immunity. This protein is primarily expressed on the cell surface, particularly in NK cells and certain T cells. It has been implicated in various diseases, particularly in the context of hematological malignancies and autoimmune diseases. Aberrant expression of KIR3DL2 has been observed in neoplastic cells in transformed mycosis fungoides and Sézary syndrome, suggesting its potential as a therapeutic target in primary cutaneous anaplastic large-cell lymphoma (pcALCL).
References:
1.Shaw J. et al. (2012). Front Immunol. 3:339. 2.Battistella M. et al. (2016). Br J Dermatol. 175(2):325-333. 3.Battistella M. et al. (2017). Blood. 130(26):2900-2902. 4.Chan AT. et al. (2005). Arthritis Rheum. 52(11):3586-3595. Hurabielle C. et al. (2018). Br J Dermatol. 179(1):197-199.